Background. Although human immunodeficiency virus (HIV)-negative men having sex with men (MSM) bear a substantial burden of human papillomavirus (HPV)-associated disease, prospective studies of genital HPV infection in this population are scarce.
The incidence of genital warts has been increasing in many western countries since the 1970s [1] . Sexually transmitted human papillomavirus (HPV) infection, usually with types 6 or 11, causes these condylomas, which incur significant morbid effects and substantial economic costs [2, 3] . In addition, genital HPV-16 infection is a major cause of penile squamous cell carcinoma, which, though rare, has either a declining, stable, or increasing incidence in recent decades, depending on country [4] [5] [6] . Like cervical cancer, the incidence of penile carcinoma is higher in developing than in developed countries [7] .
TheburdenofsomeHPV-associatedanogenitaldiseases, but not all, is higher among men having sex with men (MSM) than among men having sex with women (MSW). For example, the incidence of anal cancer, almost all of which is caused by HPV, is many times higher in MSM than in MSW [8] . On the other hand, genital condylomas may have a similar prevalence among these populations [9] .
Although anogenital HPV infection is thought to be the most common sexually transmitted infection (STI), there are few published data comparing genital HPV infection among human immunodeficiency virus (HIV)-negative MSM and MSW [10, 11] ; however, there is a substantial amount of data from the US STI surveillance system indicating that MSM are more likely than MSW to report a prior diagnosis of certain STIs, such as HIV, syphilis, gonorrhea, human herpesvirus, and hepatitis B [12] . The prevalence of HPV infection in the anal canal is much higher in MSM than in MSW [13] , but studies of genital HPV prevalence comparing MSM and MSW have found little difference or even a higher prevalence of genital HPV among MSW than among MSM [10, 14] . Among HIV-infected men, the prevalence of genital HPV is also higher in MSW than in MSM [15] . To our knowledge, however, no prospective studies have examined the incidence and clearance of genital HPV among HIV-negative MSW and MSM.
Our objective was to estimate and compare the incidence of genital HPV infections and the duration of incident infections among HIV-negative MSM and MSW. We also examined the incidence of HPV in MSM stratified into men having sex only with men (MSOM) and men having sex with both women and men (MSWM).
MATERIALS AND METHODS
Men were recruited in São Paulo, Brazil, Cuernavaca, Mexico, and Tampa, Florida from June 2005 to September 2009 for the prospective HPV Infection in Men (HIM) study. Inclusion criteria included an age of 18-70 years, no plans to relocate during the 4-year study, no self-reported history of penile or anal cancer or genital warts, and no current STI, including HIV infection. Additional details of the study design have been described elsewhere [16, 17] .
Men were recruited in São Paulo from the general population through advertisements and from a genitourinary clinic that also tests for HIV and STIs. Men who went to the clinic because of STI symptoms or for treatment were excluded. In Cuernavaca, men were recruited through a health plan and from factories and the military. Men in Tampa were recruited from a university campus and the general public. MSM were not targeted for recruitment. All participants consented to the study and received a nominal incentive for participation. The study was approved by human subjects committees at each study site.
Study Protocol
A total of 4123 men enrolled in the HIM study. Follow-up occurred at 6-month intervals for a total of 4 years. A total of 72 men acknowledged HIV infection after enrollment and were removed from further analysis. Of the remaining 4051 men, 3661 (90.4%) returned for at least the first 6-month follow-up visit.
Men completed an 88-item computer-assisted self-interview at enrollment, written in the region's primary language (Portuguese, Spanish, or English). The interview elicited information about participant demographics, substance use, and sexual behaviors. At each follow-up visit, a similar self-interview elicited information about the participant's substance use and sexual behavior since the prior visit.
At each visit, a study clinician examined the men for STI symptoms, including warts and lesions (men found to have genital warts were retained in the study). For HPV sampling, the clinician used a saline-wetted swab to sweep 360°around the coronal sulcus and glans penis, and if present, a retracted prepuce. A second swab was used to sample the entire surface of the penile shaft, and a third was used to sample the scrotum. Finally, the clinician used a separate swab to sample the anal canal. Each swab was placed in a vial of transport media (STM; Qiagen) and stored at −80°C. For detection of genital HPV, swab samples from the coronal sulcus/glans, shaft, and scrotum were combined. First-catch urine and blood were collected to test for Chlamydia trachomatis (Chlamydia LCx [Abbott Laboratories] and COBAS Amplicor CT/NG Test [Roche Diagnostics]) and herpes simplex virus 2 antibodies (HerpeSelect 2 ELISA IgG; Focus Diagnostics), respectively, at the enrollment visit and annually thereafter.
HPV Analyses
Genital specimens were analyzed for HPV DNA as described elsewhere [16] . No anal specimens were included in the current analysis. Briefly, DNA was extracted using the QIAamp Media MDx Kit (Qiagen). The polymerase chain reaction consensus primer system (PGMY 09/11) was used to amplify a fragment of the HPV L1 gene [18] . HPV genotyping was conducted on all genital specimens, using DNA probes labeled with biotin to detect 36 HPV types (including subtypes) [19] . Accuracy and potential contamination were assessed using nontemplate negative controls and CaSki DNA-positive controls. Mean β-globin positivity at enrollment and all follow-up visits was >97%. Men must have had ≥2 β-globin-positive specimens to be included in the analysis. Of 3661 men, 2 men had only 1 β-globin positive specimen over all visits, and another 5 men were excluded based on age eligibility, leaving a total of 3654 men available for analysis.
Statistical Analyses
A specimen was considered positive for any genital HPV if it was positive for ≥1 of 36 genotypes. Specimens were labeled as high risk if ≥1 of 13 types were detected (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 , and 68) [20] , regardless of the presence of other genotypes. Similarly, specimens were labeled as low risk if any of the remaining 23 types in the linear array were detected, regardless of the presence of high-risk types; thus, incidence estimates for high-and low-risk groups overlap.
Men enrolled in the study were classified as MSM, MSW, or men having no sex [21] solely based on their answers to >20 questions about recent and lifetime penetrative sexual behavior (vaginal, anal, and oral sex). Recent sexual behavior was assessed by questions about behavior in the prior 3 or 6 months or since the prior study visit. A man was classified as MSW if he acknowledged sex with only women at all study visits. A man was classified as MSM if he acknowledged sex with men at any study visit. A man was classified as having no sex if he reported no sexual behavior during his lifetime. Of 3654 men, a total of 3029 (82.9%) participants were classified as MSW, 564 (15.4%) as MSM, and 60 (1.6%) as men having no sex, with 1 man classified as missing owing to incomplete survey results. Analyses were limited to men reporting sex; thus, the analysis included 3593 men. In a secondary analysis, we stratified the MSM group into MSOM during the lifetime (n = 93) and MSWM at baseline or during study follow-up visits (n = 471). A 2-sided χ 2 test was used to assess differences in characteristics between MSM and MSW who returned for the first 6-month follow-up visit and those who did not return. An incident infection was defined as the presence of a typespecific infection at any follow-up visit when that type was absent at enrollment. Person-months were calculated as the time from specimen collection at enrollment to the date of first HPV detection or last visit. The calculation of 95% confidence intervals (CIs) for the incidence rate was based on the number of incident events and followed a Poisson distribution. For incidence calculations, the unit of analysis was the person. Incidence rate ratios along with their 95% CIs were calculated for MSOM and MSWM.
The investigation of clearance used the infection as the unit of analysis. Incident HPV infections were used to determine type-specific clearance, which was defined as 2 consecutive HPV-negative results after testing positive for that type. Because a participant could have ≥1 infection, a robust sandwich estimator was used for the covariance matrix to account for within-subject correlation of infections [22] .
The cumulative risk of genital HPV acquisition and clearance was estimated with the Kaplan-Meier method. To investigate potential heterogeneity by age and city for both MSM and MSW, stratified Kaplan-Meier curves were estimated for high-risk types, low-risk types, HPV-16, and HPV-6. The logrank test was used to compare the difference in median time to clearance and cumulative incidence between groups. Data were analyzed using R (R Foundation for Statistical Computing) and SAS 9.3 (SAS Institute) software.
RESULTS
The median follow-up time for the men was 40.4 months. Among those who enrolled in the study, retention at 6 months was 95% and 90% for MSM and MSW, respectively. Among MSM, there were no differences between men who returned for the first 6-month follow-up visit and those who did not. MSW who did not return for the visit were more likely to be aged 18-30 years (13%) rather than 45-70 years (7%; P < .001) and more likely to be single, never married rather than married (P < .001). Nonreturning MSW were also more likely to be current smokers (15%) than former smokers (7%; P < .001), more likely to be from Tampa rather than São Paulo (P < .001), and more likely to be circumcised (P < .001) (data not shown).
Among men who returned for ≥1 follow-up visit, MSM and MSW differed on most characteristics, but not all (Table 1) . For example, 43% of MSM were aged 18-30 years versus 48% of MSW (P = .01). A majority of MSM (62%) were from São Paulo; however, the median number of sexual partners (both male and female) was 1 for both MSM and MSW. In a subanalysis of MSM, similar proportions of MSOM and MSWM were from São Paulo (62% and 61%, respectively); however, 31% of MSWM and only 1% of MSOM reported a primary sexual relationship >5 years in duration (P < .001).
Within each city, the incidence rate per 1000 persons-months among MSM was modestly higher than that among MSW, although 95% CIs generally overlapped ( Table 2 ). There were 3 exceptions in which higher incidence was observed among MSM than among MSW in ≥1 city: the group of quadrivalent vaccine types, HPV-45, and HPV-11. For example, in Cuernavaca, the incidence of quadrivalent HPV vaccine types was 9.1/ 1000 person-months (95% CI, 6.2-12.9) among MSM and 5.2/ 1000 person-months (4.5-6.1) among MSW. HPV-16 was one of the most commonly acquired types, with incidence ranging from a low of 2.2/1000 person-months (95% CI, 1.8-2.7) among MSW in Cuernavaca to a high of 6.3/1000 personmonths (3.6-10.2) among MSM in Tampa.
The 12-month cumulative incidence of high-risk types among MSM was also comparable across cities (0.25; 95% CI, .21-.30 for all MSM; log-rank P = .08), whereas MSM in São Paulo acquired low-risk types more quickly than in Tampa or Cuernavaca (Figure 1 ). There were statistically significant differences in acquisition by city for groups of high-and low-risk types. Most notably, for low-risk types among MSW, the 12-month cumulative incidence rates were 39%, 21%, and 27% for São Paulo, Cuernavaca, and Tampa, respectively (P < .001). There was no difference in acquisition of HPV-16 and HPV-6 by city among MSM (Supplementary Figure 1 ). Within the larger sample of MSW, point estimates for the acquisition of HPV-16 and HPV-6 were almost identical. For example, for HPV-16, the 12-month cumulative incidence rates were 5%, 4%, and 5% for São Paulo, Cuernavaca, and Tampa, respectively, and the respective incidence rates for HPV-6 were 5%, 4%, and 4%.
Little difference in the 12-month cumulative incidence was observed by age among MSM or MSW (Figure 2 ). Point estimates for HPV-16 and HPV-6 among MSW, though significantly different, were comparable (eg, 6%, 4%, and 5% for HPV-16 among men aged 18-30, 31-44, and 45-70 years, respectively). There was no difference in the 12-month cumulative incidence rates for high-and low-risk HPV groups by age among MSM or MSW (Supplementary Figure 2) . 11 (12) 66 (14) 77 (14) 236 (8) 6-10 5 (5) 21 (4) 26 (5) 42 (1) >10 12 (13) 33 (7) 45 (8) b The χ 2 P values for all variables by comparing MSOM and MSWM were <.05, except for race (P = .05), ethnicity (P = .40), circumcision (P = .78), alcoholic drinks in the last month (P = .91), total male and/or female sex partners in the last 6 months (P = .99), frequency of insertive anal sex in the last 6 months (P = .07), anogenital warts (P = .95), and C. trachomatis infection (P = .06). Responses that were refusals or missing were not included in hypothesis testing. c The χ
2 P values for all variables by comparing MSM and MSW were ≤.01, except for ethnicity (P = .02), alcoholic drinks in the last month (P = .71), anogenital warts (P = .28), and C. trachomatis infection (P = .45). Responses that were refusals or missing were not included in hypothesis testing. d Data were collected in a subset of the full sample. e Men's self-reports from all study visits. Data were collected in a subset of the full sample.
There were no notable differences between MSM and MSW in the median months to clearance after stratifying by city (Table 3) . For example, the median duration to clearance among São Paulo men for HPV-16 genital HPV was 6.1 months (95% CI, 5.9-7.8) among MSM and 6.4 months (95% CI, 6.0-7.4) among MSW. Clearance rates for HPV-6 were also comparable among MSM and MSW in each city. When we stratified MSM by MSOM and MSWM, the incidence rates in both groups were generally comparable with incidence rate ratios indicating a higher incidence for MSOM only for the groups of any HPV and high-risk HPV and the single type HPV-45 (Table 4 ). The incidence was higher among MSWM than among MSOM only for HPV-44.
DISCUSSION
Although surveillance in the United States generally indicates increased burden among MSM for a number of STIs [12] , we observed little difference in the burden of genital HPV among MSM and MSW recruited in 3 countries. However, acquisition was high overall, with 25% of MSM (95% CI, 21%-30%) and 21% of MSW (20%-23%) acquiring a high-risk type in the first 12 months of the study. Likewise, time to clearance differed little among the 2 groups of men, with the median duration of genital HPV among MSM and MSW generally >6 months, suggesting that measures of persistence of ≤6 months may not be useful to identify clinically relevant incident genital infection among men. Giuliano et al [17] reported elsewhere that, for some groups and types of HPV, acquisition was higher overall in Brazilian men compared with men in the United States or Mexico. Because most MSM were recruited in Brazil, we stratified our analysis by country for comparison of MSM and MSW point estimates. Because stratifying affected the power of the study to observe differences between MSM and MSW and because most point estimates for incidence were higher among MSM, we may have underestimated differences among MSM and MSW; however, the differences are probably modest. Comparable incidence would be consistent with our observed median of 1 penetrative sexual partner in the 6 months before the baseline visit for both MSM and MSW.
Our findings of similar genital HPV burden among MSM and MSW across a wide age range reflect recent US surveillance data from 40 STI clinics indicating a similar burden of genital warts among MSM and MSW [9] . HPV-6 and HPV-11 are responsible for >90% of genital warts [23] , and we observed comparable incidences of these types among MSM and MSW when stratified by city. Indeed, we also observed a comparable prevalence of clinician-diagnosed genital warts among MSM and MSW in this study's baseline data.
HPV-16 is a significant etiologic agent for both penile cancer and anal cancer [4, 24] . Our observation of a comparable incidence of genital HPV-16 in MSM and MSW is consistent with the lack of a known association between sexual orientation and penile cancer. In contrast, the annual incidence of anal cancer among HIV-negative MSM is 5-25 times greater than among MSW, even though prevalence of anal HPV-16 among MSM is <3 times greater than in MSW (ie, 6.3% and 2.2%, respectively) [8, 13] . Given these genital and anal data for MSM and MSW, perhaps anopenile sex is more likely to establish productive anal HPV infection leading to malignancy in the receptive partner, whereas HPV transmission to the anal canal of MSW may occur primarily through autoinoculation or anodigital sex and lead less often to productive infection [13, 25] .
Overall, the duration of genital HPV in our study was comparable among MSM and MSW; however, we have observed an increased likelihood of HPV-16 and HPV-6 antibodies among MSM compared with MSW in the HIM study [26] , which may influence clearance of infection [27] . Although it seems logical that these mechanisms might account for increased clearance of HPV-16 and HPV-6 among MSM, we found scant evidence for this hypothesis.
It is not possible to rule out HPV clearance and reinfection between study visits. Although the study had excellent retention and employed sensitive DNA detection, it is conceivable that differential dropout rates among MSW who were smokers and single, never married affected incidence and or clearance estimates. For example, it is possible that the observed MSW incidence was biased downward owing to the increased dropout rates of single, never married MSW compared with married MSW. On the other hand, since our age-stratified analysis indicated no difference in MSW incidence for groups of high-risk and low-risk types, it is unlikely MSW estimates were biased due to younger MSW (aged 18-30 years) leaving the study; however, HPV16 and HPV6 incidence was increased in MSW aged 18-30 years which b HPV genotypes shown are those in the 9-valent vaccine in addition to types with any incidence rate >2.2/1000 person-months and an incidence rate ratio excluding unity. c Per 1000 person-months.
could have led to decreased observed incidence for these single types in the full group of men. Furthermore, although recruitment included diverse sources of men, caution should be used in generalizing the results, particularly for MSOM because the sample size is limited; however, stratification of MSM revealed a substantial number of MSWM and allowed calculations of stable longitudinal estimates in this understudied group of men. The incidence of HPV types 6, 11, 16, and 18 among MSW is not likely to be influenced by HPV vaccination in their female partners. In a subset of men asked questions about HPV vaccination, 21% of MSW reported vaccination in female sex partners; however, the prevalence of these HPV types among these MSW was not lower than that among those who reported no vaccinated partners.
In summary, we found comparable incidence of genital HPV-6 and HPV-16 in MSM and MSW and similar rates of clearance. These results are consistent with rates of penile disease in the 2 populations and comparable median numbers of sexual partners for these MSM and MSW.
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